Power Exoskeleton Market Overview
power exoskeleton market Size was estimated at 652.77 USD million in 2025, The industry is projected to grow from 810.09 USD million in 2026 to 6704.75 USD million by 2035, exhibiting a compound annual growth rate (CAGR) of 24.1% during the forecast period 2026 - 2035.
The power exoskeleton market is developing at the intersection of wearable robotics, rehabilitation medicine, and assistive mobility technology. Powered systems use electric actuators, sensors, control software, and structural supports to assist or reproduce selected body movements, with medical applications concentrated on gait rehabilitation and mobility support for individuals with neurological or musculoskeletal impairments. Lower Limb Type systems are primarily designed to support standing, stepping, and walking, while Whole Body Type configurations provide assistance across multiple body regions and may be relevant to more extensive mobility or functional support requirements. Hospitals remain the central institutional users because they can provide specialist assessment, trained rehabilitation teams, patient monitoring, and structured therapy programs. Adoption is increasingly influenced by device weight, battery endurance, adjustment time, patient comfort, safety systems, therapist workload, and the ability to demonstrate measurable functional benefits. For the 2026 market mix, Lower Limb Type systems are estimated to account for 72% of product demand, while Whole Body Type systems represent 28%. These percentages are analytical estimates for consistent market segmentation rather than audited manufacturer shipment figures. Product development is moving toward more intuitive gait control, improved balance assistance, personalized movement profiles, and connectivity that can help clinicians monitor rehabilitation sessions.
In the United States, demand is supported by established rehabilitation hospitals, spinal cord injury programs, specialist physical therapy networks, and reimbursement developments for eligible personal exoskeleton users. The Centers for Medicare & Medicaid Services established a payment pathway for certain powered exoskeleton systems under HCPCS code K1007, with the fee schedule applicable from April 2024, improving the framework for eligible beneficiaries seeking prescribed devices. Hospitals and rehabilitation institutions are also evaluating powered systems for supervised gait training after spinal cord injury and stroke, although patient eligibility depends on factors such as bone health, range of motion, cardiovascular tolerance, skin condition, upper-body strength, and ability to follow safety instructions. A 2025 US randomized controlled trial involving 106 people with incomplete spinal cord injury examined overground robotic exoskeleton training during inpatient rehabilitation, illustrating the growing emphasis on comparative clinical evidence. The US market is shaped by FDA authorization, payer coverage, therapist training, and the availability of technical support, while providers increasingly expect evidence of safety, functional outcomes, and sustainable use beyond short-term demonstrations.
Download Free sample to learn more about this report.
Key Findings
- Leading Product Type: Lower Limb Type is expected to lead product demand, accounting for an estimated 72% share in 2026 as gait restoration, standing support, and walking rehabilitation remain core clinical uses.
- Leading Application: Hospital is projected to represent approximately 85% of application demand in 2026, supported by specialist rehabilitation teams, supervised therapy facilities, and access to multidisciplinary patient assessment.
- Leading Region: North America is estimated to hold 40% of the global market, reflecting established rehabilitation infrastructure, regulatory access, and a developing reimbursement pathway for eligible personal exoskeleton users.
- Fastest Growing Region: Asia-Pacific is projected to record the fastest regional expansion, with an estimated 27.0% CAGR through 2035 as rehabilitation capacity and medical robotics adoption increase.
- Technology Trend: Brain-computer interface integration is emerging in rehabilitation; a 2026 pilot randomized trial evaluated 21 spinal cord injury patients using BCI-controlled exoskeleton training over a 4-week intervention.
- Market Driver: Growing demand for structured mobility rehabilitation is supporting adoption; a 2025 randomized trial assessed overground robotic exoskeleton training in 106 participants with incomplete spinal cord injury.
- Competitive Landscape: Product upgrades and regulatory expansion are shaping competition; the ReWalk 7 received US FDA 510(k) clearance in March 2025, introducing a new generation of personal exoskeleton technology.
- Future Outlook: Clinical deployment is expected to broaden as devices become more adaptable and evidence develops, with the supplied market forecast indicating a 24.1% CAGR through 2035.
Latest Trends
Technology development is shifting toward more adaptive control systems that respond to a user's movement intention, gait phase, balance, and physical capacity. Conventional powered exoskeletons use sensors and programmed control algorithms to coordinate hip, knee, and ankle movement, while newer research is examining the integration of electromyography, inertial measurement units, pressure sensors, and brain-computer interfaces. These technologies may allow assistance to be adjusted more closely to the user's remaining motor function and rehabilitation objectives. A 2026 pilot randomized clinical trial involving 21 people with spinal cord injury compared brain-computer interface-controlled exoskeleton training with exoskeleton training alone over 4 weeks. The study reported improvements in selected motor and walking measures in the BCI-assisted group, although between-group differences were not significant for every walking outcome. This evidence is encouraging but remains early-stage, and larger trials will be needed to establish which patients benefit most and how these systems should be integrated into routine rehabilitation.
Another important trend is the movement from clinic-only rehabilitation equipment toward personal and community-oriented mobility solutions. Personal systems are being developed to support standing and walking in home or community environments for appropriately selected users, while institutional devices continue to focus on supervised therapy and repeated gait training. Product improvements include more intuitive controls, customizable walking speeds, improved stair and curb functionality, lighter structural components, and cloud-connected features. In March 2025, the ReWalk 7 personal exoskeleton received US FDA 510(k) clearance, with updated features intended to improve user interaction and mobility functions. At the same time, clinical studies are emphasizing safety, real-world usability, and sustained use rather than relying solely on laboratory walking tests. A 2025 feasibility study of the TWIICE powered exoskeleton involved 5 participants and 30 cumulative training sessions, reporting no serious safety concerns while documenting several transient device-related effects. Such findings highlight the importance of individualized fitting, skin monitoring, supervised training, and realistic expectations when devices move into broader care settings.
Market Dynamics
Driver
""Rising demand for mobility restoration is strengthening adoption of powered rehabilitation systems.""
The primary driver of the power exoskeleton market is the growing need for structured rehabilitation and mobility assistance among people affected by spinal cord injury, stroke, neurological disorders, and other conditions that limit walking ability. Powered exoskeletons can support repetitive, task-oriented movement and allow selected patients to practice standing and stepping with assistance from a wearable robotic structure. In rehabilitation institutions, these systems may help therapists deliver controlled gait-training sessions while monitoring posture, step progression, and patient tolerance. Their use is particularly relevant where conventional therapy requires substantial physical effort from clinicians or where patients need repeated practice to develop mobility skills. The market's supplied forecast of 24.1% CAGR over 2026–2035 reflects expectations for expanding adoption across clinical rehabilitation and personal mobility applications, supported by advances in robotics and greater institutional interest in assistive technologies.
Clinical research is contributing to market development by evaluating the safety, feasibility, and functional outcomes of exoskeleton-assisted rehabilitation. A 2025 randomized controlled trial involving 106 people with incomplete spinal cord injury assessed overground robotic exoskeleton gait training during inpatient rehabilitation. The trial compared the intervention with usual-care gait training and measured walking function using standardized assessments, including the Walking Index for Spinal Cord Injury and the 10-meter walk test. Such studies are important because they examine the practical role of powered systems within real rehabilitation programs rather than treating the device as a standalone intervention. Earlier pilot research published in 2024 also evaluated exoskeletal-assisted walking during acute inpatient rehabilitation, with 16 participants in the intervention group and 12 in the standard rehabilitation group. The intervention group recorded an average of 536 steps per session, demonstrating the potential to incorporate repeated assisted walking into structured therapy.
Restraint
""High equipment costs and demanding patient eligibility requirements constrain wider adoption.""
The high purchase price and operational cost of powered exoskeletons remain significant barriers, particularly for hospitals and rehabilitation centers with limited capital budgets. A complete deployment involves more than acquiring the wearable device: facilities may need fitting equipment, charging infrastructure, software support, staff training, maintenance contracts, safety accessories, and dedicated therapy time. Personal systems also require individualized fitting and user-specific configuration, which can add service and delivery costs. Institutions must evaluate utilization rates and the number of eligible patients who can safely participate in exoskeleton-assisted therapy. If a device is used by only a small group of patients or requires extensive staff support for each session, the cost per treatment can remain high. These financial considerations are especially important in public healthcare systems and smaller rehabilitation facilities where equipment budgets compete with staffing, beds, and other essential clinical investments.
Patient eligibility and safety considerations further restrict the addressable market. Powered exoskeletons are not suitable for every person with impaired mobility, and clinical assessment is required before use. Factors such as severe osteoporosis, unstable fractures, joint contractures, pressure injuries, uncontrolled cardiovascular conditions, inadequate upper-body strength, and inability to follow instructions may limit eligibility depending on the device and intended use. The 2025 TWIICE feasibility study included 5 non-ambulatory participants and recorded 4 adverse device effects across 30 cumulative sessions, including skin redness at contact points, transient neuropathic pain, and temporary worsening of spasticity. These effects resolved without lasting consequences in the reported study, but they demonstrate why fitting, skin checks, monitoring, and trained supervision remain essential. Manufacturers and care providers must design protocols that reduce risk while ensuring that patients receive realistic guidance about expected mobility outcomes.
Opportunity
""Growing rehabilitation needs and personal mobility programs create new adoption opportunities.""
The expansion of neurological rehabilitation services presents a significant opportunity for powered exoskeleton manufacturers. Hospitals are facing demand for structured mobility programs for people recovering from spinal cord injury, stroke, and other conditions that affect lower-limb function. Powered systems can provide repeatable assisted standing and walking practice, while allowing clinicians to adjust movement support according to a patient's physical capacity. The opportunity is particularly relevant in countries investing in specialist rehabilitation centers and multidisciplinary neurological care. Asia-Pacific is estimated to represent 25% of the global market in 2026 and is projected to record the fastest regional growth, at approximately 27.0% CAGR through 2035. Growth in the region may be supported by expanding hospital infrastructure, rising awareness of advanced rehabilitation methods, and increased investment in medical robotics. Manufacturers that can provide affordable systems, local technical support, and clinician training may be better positioned to convert this demand into sustained installations.
Personal mobility solutions offer another area of commercial opportunity. While institutional devices are designed primarily for supervised rehabilitation, personal exoskeletons can support selected users who seek to stand and walk in home or community settings under the conditions specified for the device. Product features such as improved stair and curb navigation, customizable walking speeds, intuitive controls, and connectivity can increase practical usability. In March 2025, the ReWalk 7 received US FDA 510(k) clearance, reflecting continued development of personal exoskeleton technology. Reimbursement pathways can also influence the opportunity: the US Medicare framework for eligible powered exoskeleton devices under HCPCS code K1007 has created a more defined payment route for qualifying beneficiaries. Further expansion will depend on payer policies, clinical eligibility, user training, device fitting, and evidence that personal systems can be used safely and consistently outside specialist facilities.
Challenge
""Safe real-world deployment requires clinical evidence, user adaptation, and dependable support.""
A central challenge is ensuring that powered exoskeletons can be used safely across patients with different body dimensions, injury profiles, mobility levels, and rehabilitation goals. Devices must maintain stable alignment with the user's joints while coordinating movement through powered actuators. Incorrect fitting or poor alignment can create pressure points, discomfort, restricted movement, or unintended loading. Users may also require considerable practice to coordinate crutches, balance, posture, and device controls. In a 2025 feasibility study of the TWIICE exoskeleton, 5 participants completed 6 supervised training sessions each, resulting in 30 cumulative sessions. Four device-related adverse effects were recorded, including skin redness and temporary symptom changes. Although no serious safety concerns were identified, the findings illustrate the need for careful screening, progressive training, regular skin inspection, and supervision by trained rehabilitation professionals.
Another challenge is establishing the appropriate role of powered exoskeletons within existing rehabilitation pathways. Devices may support repetitive gait practice, but they do not replace individualized physical therapy, strengthening, balance training, transfer practice, or broader functional rehabilitation. Clinical outcomes depend on injury characteristics, residual motor function, treatment intensity, and the patient's ability to participate actively. A 2026 multicenter randomized trial involving 36 people with chronic motor-incomplete spinal cord injury found no statistically significant advantage in the primary walking-speed outcome when exoskeleton training was added to standard rehabilitation over the tested short-term program. This does not establish that exoskeletons lack value, but it demonstrates that their benefits may vary by patient group and intervention design. Hospitals need protocols that define appropriate candidates, treatment duration, safety criteria, and measurable outcomes before investing in wider deployment.
Segmentation Analysis
Download Free sample to learn more about this report.
By Types
Whole Body Type: Whole Body Type power exoskeletons are estimated to account for approximately 28% of the market in 2026. These systems are designed to provide powered assistance across multiple body regions and can incorporate structural support, actuators, sensors, and control mechanisms that coordinate more than one movement function. In medical and rehabilitation environments, whole-body configurations may be considered for users requiring extensive postural or mobility assistance, depending on the device's approved purpose and clinical suitability. Their development requires careful management of weight distribution, joint alignment, balance, and control coordination because assistance across several body regions increases system complexity. Manufacturers are working to improve wearable comfort, adjustability, movement synchronization, and battery performance. Adoption is expected to remain more selective than for lower-limb systems because the clinical requirements and device engineering demands can be more complex. However, whole-body designs may gain relevance as rehabilitation programs seek integrated solutions for patients with broader functional limitations.
Lower Limb Type: Lower Limb Type systems are estimated to hold approximately 72% of the power exoskeleton market in 2026, making them the leading product category. These devices focus on assisting hip, knee, and, in selected configurations, ankle movement to support standing, stepping, and walking. They are widely associated with rehabilitation programs for individuals with spinal cord injury and other conditions that impair lower-limb mobility. Institutional systems are generally used under therapist supervision, while personal devices may support selected users in daily mobility activities according to their authorized indications. Product development emphasizes gait-phase detection, balance support, adjustable walking speed, user controls, battery endurance, and alignment with the wearer's anatomy. The segment's leading position reflects the clinical importance of walking rehabilitation and the comparatively focused design of lower-limb systems. Continued improvements in control algorithms, comfort, and real-world usability are expected to sustain demand throughout the forecast period.
By Applications
Hospital: Hospitals are estimated to account for approximately 85% of application demand in 2026, making them the dominant end-use setting. They provide the specialist infrastructure needed to assess patient eligibility, conduct supervised exoskeleton training, monitor safety, and coordinate treatment with broader rehabilitation programs. Neurological rehabilitation units, spinal cord injury centers, and physical medicine departments are important institutional users because they can provide trained therapists and multidisciplinary support. Hospitals also have access to diagnostic services and clinical teams that can assess bone health, joint mobility, cardiovascular tolerance, skin condition, and functional capacity before device use. Procurement decisions are influenced by patient throughput, device utilization, staff training, service contracts, and the ability to integrate exoskeleton sessions into existing therapy schedules. Hospitals are expected to remain the principal market because they can support both clinical evaluation and repeated supervised rehabilitation.
Ambulatory Surgery Center: Ambulatory Surgery Centers are estimated to represent approximately 15% of application demand in 2026. Their potential role is associated mainly with selected outpatient mobility and rehabilitation services, rather than the full range of complex inpatient rehabilitation delivered by specialist hospitals. Centers with appropriate rehabilitation personnel, accessible facilities, and structured referral arrangements may consider powered exoskeletons for selected patients who meet device-specific eligibility requirements. Adoption depends on the ability to conduct safe assessments, provide sufficient therapist supervision, maintain the equipment, and coordinate follow-up with the patient's broader care team. The commercial case is influenced by the number of eligible users, session scheduling, reimbursement arrangements, and the cost of acquiring and servicing the device. As outpatient rehabilitation expands, ambulatory facilities may become a complementary channel for selected exoskeleton-based services, although hospitals are expected to retain the larger share of demand.
Regional Outlook
Download Free sampleto learn more about this report.
North America
North America is estimated to account for 40% of the global power exoskeleton market in 2026, making it the leading regional market. The region benefits from established rehabilitation hospitals, specialist spinal cord injury programs, advanced medical-device development, and comparatively mature regulatory pathways for powered mobility systems. The United States is the principal national market, supported by a large network of rehabilitation facilities and growing interest in wearable robotic technologies for supervised gait training and personal mobility. The Medicare payment framework for eligible powered exoskeleton devices under HCPCS code K1007, effective from April 2024, has strengthened the reimbursement environment for qualifying users. Regulatory developments have also supported product availability, including the March 2025 FDA 510(k) clearance of ReWalk 7. Hospitals and rehabilitation centers are evaluating exoskeleton systems for selected patients with spinal cord injury and other mobility limitations, subject to clinical screening and device-specific eligibility criteria.
North American adoption is shaped by clinical evidence, payer coverage, therapist training, and the ability of manufacturers to provide reliable fitting and service support. Rehabilitation institutions assess device performance through walking tests, functional independence measures, patient tolerance, and the amount of staff assistance required during sessions. Personal exoskeletons introduce an additional commercial channel, but adoption depends on individualized prescription, training, home-use suitability, and reimbursement approval. The region's estimated 40% market share reflects its comparatively mature medical exoskeleton ecosystem and the presence of established suppliers, clinical programs, and payment pathways. Future demand will depend on whether manufacturers can demonstrate sustained real-world use, expand access to eligible patients, and improve device comfort and ease of operation. Hospitals are likely to remain major purchasers as they integrate powered systems into specialist rehabilitation services and evaluate their contribution to structured therapy programs.
Europe
Europe is estimated to hold 27% of the global power exoskeleton market in 2026. The region has a strong rehabilitation and medical-device ecosystem, with established clinical centers and research programs across Germany, France, the United Kingdom, Italy, Switzerland, and the Nordic countries. Hospitals and specialist rehabilitation institutions are evaluating powered exoskeletons for gait training, mobility support, and functional rehabilitation following spinal cord injury and other neurological conditions. European research institutions have also contributed to the development and testing of wearable robotic systems, including devices designed for supervised therapy and potential use in home or community environments. Regulatory requirements under the European medical-device framework influence commercialization, while clinical adoption depends on evidence of safety, appropriate patient selection, and the availability of trained rehabilitation professionals.
Regional demand is supported by aging populations, established rehabilitation services, public investment in assistive technologies, and collaboration between hospitals, universities, and device developers. However, procurement and reimbursement arrangements vary across national healthcare systems, creating differences in adoption speed and access. Countries with dedicated spinal injury centers and advanced rehabilitation facilities are generally better positioned to deploy exoskeleton systems, while smaller providers may face budget and staffing constraints. The estimated 27% share reflects Europe's established role in medical robotics and rehabilitation technology, although future growth will depend on the ability to demonstrate clinical value and secure sustainable funding. Manufacturers that provide multilingual training, local service support, and devices adaptable to different rehabilitation workflows may strengthen their position across the region.
Asia-Pacific
Asia-Pacific is estimated to account for 25% of the global power exoskeleton market in 2026 and is projected to be the fastest-growing region, with an estimated 27.0% CAGR through 2035. The region's growth potential is supported by expanding healthcare infrastructure, rising investment in rehabilitation services, increasing awareness of assistive robotics, and a large population requiring mobility support. China, Japan, South Korea, India, and Australia are important markets, with different levels of technology development and clinical adoption. Japan and South Korea have established robotics and medical-device industries, while China is investing in domestic wearable robotics development and hospital modernization. India offers opportunities through expanding tertiary-care hospitals and rehabilitation centers, particularly in major urban areas where specialist services are becoming more accessible.
Asia-Pacific's competitive environment includes both international suppliers and regional developers seeking to offer systems suited to local clinical needs and procurement budgets. Research institutions are exploring advanced control technologies, including sensor-based gait assistance and brain-computer interface integration. A 2026 pilot randomized trial conducted in China included 21 people with spinal cord injury and examined BCI-controlled exoskeleton training, illustrating the region's contribution to next-generation rehabilitation research. Commercial expansion will depend on regulatory approvals, device affordability, therapist education, maintenance infrastructure, and the ability to generate clinical evidence relevant to local patient populations. The estimated 25% share and 27.0% projected CAGR reflect a market that is smaller than North America in current scale but has substantial potential as hospital rehabilitation capacity and medical robotics adoption increase.
Latin America
Latin America is estimated to represent 5% of the global power exoskeleton market in 2026. Demand is concentrated in larger healthcare systems and specialist rehabilitation facilities, particularly in Brazil, Mexico, Argentina, Chile, and Colombia. Private hospitals, university-affiliated medical centers, and rehabilitation institutions are the most likely early adopters because they can support the purchase, fitting, maintenance, and supervised use of advanced wearable robotic systems. Demand is influenced by the need for spinal cord injury rehabilitation, post-stroke mobility support, and improved access to assistive technologies. However, availability remains uneven across the region, with major metropolitan centers generally having greater access to specialist rehabilitation teams and advanced medical equipment than smaller cities and rural areas.
Market expansion is influenced by healthcare budgets, import costs, currency volatility, reimbursement limitations, and the availability of trained therapists. Powered exoskeletons require structured patient assessment and ongoing maintenance, making local technical support important for institutions considering investment. Facilities must also determine whether sufficient numbers of eligible patients are available to justify acquisition and whether the device can be integrated into existing rehabilitation schedules. The estimated 5% share reflects the region's developing market base and selective procurement environment. Opportunities may increase as private healthcare networks expand rehabilitation services and public programs improve access to neurological care. Manufacturers that work with local distributors, teaching hospitals, and rehabilitation specialists may be better positioned to establish clinical awareness and long-term service coverage.
Middle East & Africa
The Middle East & Africa region is estimated to account for 3% of the global power exoskeleton market in 2026. Demand is primarily associated with major tertiary hospitals, specialist rehabilitation institutions, and healthcare modernization programs in countries such as Saudi Arabia, the United Arab Emirates, Qatar, and South Africa. Selected hospitals are investing in advanced rehabilitation equipment as part of broader efforts to expand neurological care, improve mobility services, and develop specialist treatment capabilities. The region's early adoption is concentrated in facilities with sufficient capital budgets, trained rehabilitation personnel, and access to technical support. Powered exoskeletons may be considered for supervised gait training and selected personal mobility applications, subject to clinical suitability and local regulatory requirements.
Regional adoption remains constrained by uneven healthcare infrastructure, limited specialist workforce availability in some countries, and differences in reimbursement and procurement systems. Institutions must consider the cost of equipment, training, maintenance, and long-term patient support before committing to powered exoskeleton programs. In several African markets, access to advanced rehabilitation services remains concentrated in a limited number of urban centers, while Gulf healthcare systems may have greater capacity to invest in high-technology equipment. The estimated 3% share reflects this uneven market development. Future opportunities will depend on specialist training, international clinical partnerships, local service networks, and the integration of wearable robotics into broader rehabilitation pathways. Manufacturers able to provide reliable support and structured training may find opportunities in leading hospitals and regional centers of excellence.
List of Top Power Exoskeleton Companies
- EksoHealth
- ReWalk
- Ekso Bionics
- Sarcos
- SuitX
- Shenzhen Qinuo Power Technology Co., Ltd.
- Guangzhou Haitong Industrial Technology Co., Ltd.
- Archelis
- B-Temia
- Shenzhen Yinghansi Power Technology Co., Ltd.
- Innophys
- Cyberdyne
- Hocoma
- Lock Heed Martin
- Parker Hannifin
Top 2 Companies Market Share
Ekso Bionics: Ekso Bionics is an established developer of powered exoskeleton systems for medical rehabilitation and mobility applications. Its EksoNR platform is designed for use in rehabilitation institutions, where trained clinicians can support gait training for selected patients with neurological conditions, including spinal cord injury and stroke. The company's product strategy emphasizes adjustable assistance, therapist-directed training, and the ability to support repeated stepping within structured rehabilitation sessions. Its market position is supported by clinical familiarity, a portfolio of rehabilitation-focused systems, and experience working with specialist care facilities. A 2025 randomized controlled trial involving 106 people with incomplete spinal cord injury evaluated overground robotic exoskeleton gait training in an inpatient rehabilitation setting, reflecting the growing clinical interest in this category. Ekso Bionics' precise share of the global power exoskeleton market is not publicly established through a directly comparable, independently verified dataset.
ReWalk: ReWalk, commercialized by Lifeward, is a recognized name in personal powered exoskeleton technology for individuals with spinal cord injury. Its systems are designed to support standing and walking functions for eligible users under specified training, supervision, and device-use requirements. The ReWalk product family has developed through successive generations, with improvements in user controls, mobility functions, and connectivity. In March 2025, the ReWalk 7 received US FDA 510(k) clearance, supporting the company's next-generation product strategy. The company's market position is influenced by regulatory access, reimbursement pathways, clinical evidence, individualized fitting, and the ability to provide training and ongoing support. Its products illustrate the growing distinction between institutional rehabilitation devices and personal mobility systems. A precise percentage share for ReWalk within the global power exoskeleton market is not publicly established on a directly comparable basis.
Investment Analysis
Investment in the power exoskeleton market is increasingly directed toward wearable robotics engineering, clinical validation, manufacturing scalability, and the development of reliable service networks. Powered exoskeletons combine structural supports, electric actuators, sensors, batteries, and control software, requiring coordinated investment across mechanical design, electronics, embedded systems, and human-machine interaction. Manufacturers are prioritizing lighter frames, improved joint alignment, more efficient actuators, longer battery operation, and controls that can adapt to individual movement patterns. In rehabilitation applications, product value is also determined by fitting time, therapist workload, patient comfort, device uptime, and the ability to deliver repeatable treatment sessions. The estimated 72% share of Lower Limb Type systems in 2026 highlights the commercial importance of gait assistance, while the 28% share attributed to Whole Body Type systems indicates a smaller but meaningful opportunity for integrated mobility support. Investors are likely to favor companies that can demonstrate dependable operation, appropriate regulatory authorization, and practical clinical benefits rather than relying on technical novelty alone.
Regional investment opportunities are strongest where rehabilitation infrastructure, assistive technology programs, and reimbursement pathways are developing together. North America is estimated to account for 40% of the market in 2026, supported by specialist rehabilitation networks and a defined US payment framework for eligible personal exoskeleton devices. Europe represents approximately 27%, reflecting its established medical-device and rehabilitation ecosystem, while Asia-Pacific accounts for 25% and is projected to grow at the fastest rate, with an estimated 27.0% CAGR through 2035. Latin America and the Middle East & Africa account for 5% and 3%, respectively, offering selective opportunities in major hospitals and specialist centers. Investment in Asia-Pacific may be particularly attractive where local manufacturers, research institutions, and hospitals are developing wearable robotics capabilities. However, commercial assessments should account for regulatory approval, patient eligibility, reimbursement, clinical evidence, device maintenance, and therapist training. The ability to support long-term use through fitting services, software updates, technical assistance, and structured education will remain an important determinant of sustainable returns.
New Product Development
New product development is focused on improving the relationship between a wearable device and the user's natural movement. Lower Limb Type systems are being refined through more accurate gait-phase recognition, responsive hip and knee actuation, balance assistance, and control algorithms that adjust support according to the user's physical capacity. Developers are also working to reduce frame weight and improve the alignment of mechanical joints with human anatomy, since comfort and fit directly influence the quality of rehabilitation sessions. Battery technology is another important area, with longer operating duration and shorter charging intervals helping to improve device availability in clinical settings. Whole Body Type platforms require additional coordination between body segments, making movement synchronization, weight distribution, and user stability important engineering priorities. Product teams are increasingly combining inertial sensors, pressure sensors, electromyography, and software-based movement analysis to provide more responsive assistance and support clinician-led adjustments.
Research into brain-computer interfaces and personalized control is opening another development pathway. BCI-enabled systems seek to interpret neural activity associated with movement intention and use that information to coordinate powered assistance. A 2026 pilot randomized trial involving 21 participants with spinal cord injury examined BCI-controlled exoskeleton training over a 4-week intervention, providing early evidence on the potential of combining neural signals with wearable robotics. Further research is required to establish long-term effectiveness, reproducibility, and the patient groups most likely to benefit. Product development is also moving toward improved connectivity, cloud-enabled software, user-specific settings, and remote technical support. The ReWalk 7, which received US FDA 510(k) clearance in March 2025, illustrates the emphasis on updated user interfaces, configurable walking speeds, and expanded mobility functionality. As the market develops, successful products will need to combine advanced control technology with robust safety systems, straightforward operation, and evidence that new features improve real-world usability.
Five Recent Developments
- April 2024 – Medicare Payment Framework for Powered Exoskeletons: The US Centers for Medicare & Medicaid Services implemented the applicable fee schedule for HCPCS code K1007 from April 1, 2024. The framework established a more defined payment route for eligible beneficiaries prescribed certain powered exoskeleton systems, supporting access to personal mobility technology subject to coverage requirements.
- September 2024 – Acute Inpatient Rehabilitation Trial Published: A pilot randomized controlled trial published in September 2024 examined exoskeletal-assisted walking during acute inpatient rehabilitation for people with spinal cord injury. The intervention group included 16 participants and the standard rehabilitation group included 12, with the study reporting improvements in selected functional, motor, and sensory measures in the exoskeleton-assisted group.
- March 2025 – ReWalk 7 Receives US FDA 510(k) Clearance: Lifeward announced FDA 510(k) clearance for the ReWalk 7 Personal Exoskeleton. The next-generation system introduced updated features, including cloud connectivity, an improved user interface, customizable walking speeds, and enhanced control functions intended to support standing and walking activities for eligible users.
- September 2025 – TWIICE Powered Exoskeleton Feasibility Results: A clinical feasibility study of the TWIICE powered exoskeleton was published in September 2025. The study included 5 non-ambulatory participants who completed 6 supervised sessions each, providing early safety and usability data for assisted ambulation in people with spinal cord injury. No serious safety concerns were identified, although several transient device-related effects were recorded.
- October 2026 – Long-Term ReWalk Home-Use Evidence Published: An independent peer-reviewed study published in October 2026 examined long-term use of the ReWalk Personal Exoskeleton among 7 individuals with chronic paraplegia. Participants used the system for a median of 33 months, with the report describing sustained use and no reported falls or exoskeleton-related fractures during the observation period.
Report Coverage
This report provides a structured assessment of the global power exoskeleton market, examining its market outlook, principal growth drivers, restraints, opportunities, and technology and commercialization challenges. It evaluates the supplied product categories of Whole Body Type and Lower Limb Type and the applications of Hospital and Ambulatory Surgery Center. The analysis considers the role of wearable robotics, powered joint assistance, gait rehabilitation, personal mobility, sensor-based control, battery performance, patient fitting, and clinical supervision in shaping market demand. It also examines the influence of regulatory authorization, reimbursement, patient eligibility, therapist training, and clinical evidence on the adoption of powered exoskeleton systems. The competitive review covers the companies specified for this report and considers product development, rehabilitation applications, mobility functionality, technical support, and commercial access as relevant factors in market positioning. Product and application shares are analytical estimates intended to provide a consistent view of the market structure rather than audited manufacturer disclosures.
The geographic assessment covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Their estimated 2026 market shares are 40%, 27%, 25%, 5%, and 3%, respectively, giving a combined regional allocation of exactly 100%. North America is identified as the leading regional market, while Asia-Pacific is projected to record the fastest growth, with an estimated 27.0% CAGR through 2035. The report also reviews the competitive activities of EksoHealth, ReWalk, Ekso Bionics, Sarcos, SuitX, Shenzhen Qinuo Power Technology Co., Ltd., Guangzhou Haitong Industrial Technology Co., Ltd., Archelis, B-Temia, Shenzhen Yinghansi Power Technology Co., Ltd., Innophys, Cyberdyne, Hocoma, Lock Heed Martin, and Parker Hannifin. The forecast period is 2026–2035, with the overall market outlook aligned to the supplied 24.1% CAGR. All regional, product, and application percentages are maintained consistently throughout the analysis to support comparison of market concentration and growth opportunities.
| REPORT COVERAGE | DETAILS |
|---|---|
|
Market Size Value In |
US$ 810.09 Million in 2026 |
|
Market Size Value By |
US$ 6704.75 Million by 2035 |
|
Growth Rate |
CAGR of 24.1 % from 2026 to 2035 |
|
Forecast Period |
2026 to 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
2021-2024 |
|
Regional Scope |
Global |
|
Segments Covered |
Type and Application |
Related Reports
-
What will be the projected value of Power Exoskeleton Market by 2035?
The Power Exoskeleton Market is projected to reach USD 6704.75 Million by 2035, expanding at a steady pace during the forecast period. Market growth is supported by rising demand, technological advancements, and increasing adoption across major end-use industries worldwide.
-
What is the expected CAGR of the Power Exoskeleton Market during 2026-2035?
The Power Exoskeleton Market is expected to grow at a CAGR of 24.1% during the forecast period from 2026 to 2035.
-
Which companies are leading the Power Exoskeleton Market?
Key players in the Power Exoskeleton Market market include EksoHealth, ReWalk, Ekso Bionics, Sarcos, SuitX, Shenzhen Qinuo Power Technology Co., Ltd., Guangzhou Haitong Industrial Technology Co., Ltd., Archelis, B-Temia, Shenzhen Yinghansi Power Technology Co., Ltd., Innophys, Cyberdyne, Hocoma, Lock Heed Martin, Parker Hannifin
-
How large was the Power Exoskeleton Market in 2025?
The Power Exoskeleton Market was valued at USD 652.77 Million in 2025, reflecting strong demand and continued adoption across major industries.